Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE SODIUM versus BRINZOLAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE SODIUM versus BRINZOLAMIDE.
ACETAZOLAMIDE SODIUM vs BRINZOLAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetazolamide is a carbonic anhydrase inhibitor. It reversibly inhibits the enzyme carbonic anhydrase, which catalyzes the reversible hydration of carbon dioxide and dehydration of carbonic acid. This results in increased excretion of bicarbonate, sodium, potassium, and water in the urine, leading to metabolic acidosis. Additionally, it reduces aqueous humor secretion in the eye, lowering intraocular pressure, and can decrease cerebrospinal fluid production.
Brinzolamide is a carbonic anhydrase inhibitor. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor secretion and thereby lowering intraocular pressure.
Adult: 250-500 mg IV or IM every 12-24 hours; for edema, 250-375 mg IV once daily in morning. For glaucoma, 250-1000 mg IV or IM daily in divided doses.
1 drop of 1% solution in the affected eye(s) twice daily.
None Documented
None Documented
Clinical Note
moderateBrinzolamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brinzolamide."
Clinical Note
moderateBrinzolamide + Fluconazole
10-15 hours (prolonged in renal impairment; cirrhosis increases t1/2 to 20-30 h).
Terminal elimination half-life: 111 days (due to extensive red blood cell binding); clinical context: steady-state reached after 8–12 weeks of dosing
Primarily renal (90% unchanged via tubular secretion). <2% biliary/fecal.
Renal: approximately 60% unchanged; biliary/fecal: minimal (<10%)
Category C
Category A/B
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
"The metabolism of Fluconazole can be decreased when combined with Brinzolamide."